Biomed Lublin Wytwornia Surowic i Szczepionek SA is a renowned company that embodies strong values and a clear corporate philosophy. With its dedication to excellence, innovation, and customer satisfaction, Biomed Lublin strives to provide high-quality vaccines and serum products. The company emphasizes transparency, integrity, and responsible corporate citizenship in all its operations. Biomed Lublin's commitment to research and development ensures the continuous improvement of its products, enabling it to contribute significantly to the healthcare industry. By prioritizing safety, efficacy, and ethical business practices, Biomed Lublin Wytwornia Surowic i Szczepionek SA demonstrates its dedication to improving global health and saving lives.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily present in Poland.

Biomed Lublin Wytwornia Surowic i Szczepionek SA has achieved several significant milestones. The company has successfully developed and manufactured a range of high-quality vaccines and sera, contributing to the improvement of public health worldwide. It has obtained various regulatory approvals, ensuring the safety and efficacy of its products. Biomed Lublin has also established partnerships with reputable international organizations and pharmaceutical companies, enhancing its global presence in the biopharmaceutical industry. Additionally, the company has invested in research and development, leading to advancements in vaccine production technology and the development of new innovative products. These achievements showcase Biomed Lublin Wytwornia Surowic i Szczepionek SA's dedication to excellence and its commitment to addressing global healthcare challenges.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish pharmaceutical company specializing in the development and production of vaccines and serums. With a rich history spanning several decades, Biomed Lublin has emerged as a key player in the healthcare industry. Established in 1950, the company has continuously evolved, leveraging its expertise in immunology and microbiology to create innovative biopharmaceutical solutions. Over the years, Biomed Lublin has contributed significantly to public health, delivering high-quality vaccines to protect against various diseases. Their commitment to research, state-of-the-art facilities, and stringent quality controls has earned Biomed Lublin Wytwornia Surowic i Szczepionek SA a reputation for excellence in the pharmaceutical market.

The main competitors of Biomed Lublin Wytwornia Surowic i Szczepionek SA in the market are other pharmaceutical companies operating in the vaccine and serum production industry. Some notable competitors include GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., and Johnson & Johnson.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily active in the pharmaceutical and biotechnology industries.

The business model of Biomed Lublin Wytwórnia Surowic i Szczepionek SA is focused on the production and distribution of vaccines, serums, and biological products. As a professional stock website, we provide information on the business strategies and operations of Biomed Lublin Wytwórnia Surowic i Szczepionek SA. This Polish company aims to cater to the healthcare industry by delivering high-quality healthcare solutions through the development and manufacturing of vaccines and serums. Biomed Lublin Wytwórnia Surowic i Szczepionek SA's business model revolves around meeting the growing demands for immunization and contributing to public health both nationally and globally.

Synthaverse için şu anki KGV hesaplanamıyor.

Synthaverse için mevcut KUV şu anda hesaplanamıyor.

Synthaverse için AlleAktien Kalite Skoru 5/10'dur.

Synthaverse için şu an ciro hesaplanamıyor.

Synthaverse için şu anda kar hesaplanamıyor.

Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish company specializing in the production of vaccines, serum, and other biological products. The company was established in 1950 and has experienced continuous growth since then. Biomed Lublin is an important member of the Polish biotechnology industry and has established itself as a key supplier of medical products. The company focuses on the production of vaccines, including tetanus, diphtheria, scarlet fever, polio, hepatitis A and B, typhoid, and rabies. Additionally, Biomed Lublin produces serum, antitoxins, and other antibody products that are distributed worldwide. The company's blood products and plasmapheresis products department is also an integral part of its services. Biomed Lublin has multiple state-of-the-art production facilities and the necessary equipment to ensure the quality and effectiveness of its products. It is certified and complies with Good Manufacturing Practices (GMP) standards, ensuring strict quality assurance throughout all phases of product development and manufacturing. Moreover, Biomed Lublin is involved in research and development, collaborating with leading academic institutions in Poland and abroad to create the best possible scientific basis. Exporting its products to countries worldwide is one of the core businesses of Biomed Lublin, with current partner countries including Japan, China, Brazil, Russia, and India. In conclusion, Biomed Lublin is an established biotechnology company with a long history and expertise in the production and distribution of biological products. It has a strong international network and is capable of offering high-quality products at competitive prices.

Synthaverse, yılda kez dağıtılmak üzere 0 PLN tutarında temettü ödemektedir.

Synthaverse için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Synthaverse şirketinin ISIN kodu PLBMDLB00018’dir.

Synthaverse 'nin WKN'si A1J10U 'dir.

Synthaverse için Ticker SVE.WA’dir.

Son 12 ay içerisinde Synthaverse, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Synthaverse, tahmini olarak 0 PLN tutarında bir temettü ödemesi yapacak.

Synthaverse şirketinin mevcut temettü verimi .

Synthaverse dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Synthaverse, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 PLN tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Synthaverse, 'Sağlık' sektörüne atanmıştır.

Son Synthaverse tarihinde 0 PLN tutarındaki en son temettüyü alabilmek için, hisseyi 08.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 08.10.2024 olarak gerçekleşti.

2023 yılında Synthaverse tarafından 0 PLN olarak temettüler dağıtıldı.

Synthaverse hisselerinin temettüleri PLN olarak dağıtılır.